CFO Mark Kaye adds Carelon oversight; Haytaian transitions; FY2026 guidance reaffirmed

Elevance Health, Inc.

Peter Haytaian steps down as Carelon President effective May 4, 2026; will serve as Special Advisor through Dec 31, 2026.
CFO Mark Kaye expands role to oversee Carelon operations including pharmacy, behavioral, value-based care, and care delivery.
Felicia Norwood consolidates Commercial and Government Health Benefits under a single accountable structure.
FY2026 adjusted EPS guidance reaffirmed at least $25.50; reported EPS at least $22.30 (incl. $3.20 net unfavorable items).
Benefit expense ratio guidance reaffirmed at 90.2% +/- 50 bps for full year 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.